ClinicalTrials.gg
CompletedNCT07379762Updated Jan 30, 2026

Intramuscular Versus Rectal Diclofenac for Pain Relief After Cesarean Section in Women

A Phase 4 interventional study of Diclofenac 75mg and Diclofenac 50mg in Cesarean Section Pain, Diclofenac and Suppository, sponsored by CMH Multan Institute of Medical Sciences. Completed at 1 site in Pakistan. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by CMH Multan Institute of Medical Sciences · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Feb 2025, registered Jan 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing diclofenac in Pain, Postoperative — 1 open to participants now, 1 under way, none of them phase 3. Diclofenac · Pain, Postoperative.

Enrollment
12th of 17
60 · median 98
Started
2025
with 1 other
Phase 4
3 of 17
none open now
Registered
16th of 17
by date
Lead sponsor
1 of 17
CMH Multan Institute of Medical Sciences

Among the 17 studies testing diclofenac in Pain, Postoperative, this one is the 12th largest by enrollment, is one of 2 that started in 2025, is one of 3 in phase 4, and was the 16th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

1 of the 17 studies testing diclofenac in Pain, Postoperative is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About diclofenac

Diclofenac: first FDA approval 1988 (VOLTAREN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 20 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing diclofenac in Pain, Postoperative, or all of them as a file.
02

Study summary

The goal of this clinical study is to find out which way of giving diclofenac sodium provides better pain relief after a planned cesarean section: an injection into the muscle or a suppository given through the rectum. Diclofenac is a commonly used pain-relieving medicine after surgery.

Women often experience moderate pain after a cesarean section, and effective pain control helps with early movement, breastfeeding, and overall recovery. Different methods of giving the same medicine may work differently and may affect how comfortable patients feel after surgery. This study compares these two methods to see which one reduces pain more effectively.

Researchers will compare post-operative pain levels in women who receive intramuscular diclofenac with those who receive rectal diclofenac after elective cesarean section.

The main questions this study aims to answer are:

  • Does intramuscular diclofenac provide better pain relief than rectal diclofenac after cesarean section?
  • Is there a difference in the need for additional (rescue) pain medicine between the two groups?

Participants will be women aged 20 to 45 years who are undergoing a planned cesarean section at term. A total of 60 women will take part in the study. They will be randomly assigned to one of two groups:

  • One group will receive diclofenac as an intramuscular injection every 8 hours for the first 24 hours after surgery.
  • The other group will receive diclofenac as a rectal suppository every 8 hours for the same period.

All participants will receive standard spinal anesthesia for surgery. Pain will be measured using a simple pain scale at 1, 6, 12, and 24 hours after the operation. If a participant reports significant pain, additional pain medicine will be given.

The results of this study will help doctors choose the most effective and comfortable method of pain relief for women after cesarean section.

03

Conditions studied

  • Cesarean Section Pain
  • Diclofenac
  • Suppository
  • Postoperative Pain

Browse trials for

Keywords

  • cesarean section
  • postoperative pain
  • Diclofenac suppository
  • Diclofenac intramuscular
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 37 - 42 weeks of gestation
  • planned to go for elective cesarean section

Exclusion criteria

Exclusion Criteria:

  • Women already on long-term analgesics
  • known to any of the study medications
  • known diabetics (chronic or GDM)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    IM Diclo

    Intramuscular diclofenac will be given for first 24-hours

    Drug: Diclofenac 75mg

  • Active comparator
    Rectal Diclo

    Diclofenac suppository will be given after caesarean section for first 24-hours

    Drug: Diclofenac 50mg

Interventions

  • DrugDiclofenacStudies of DiclofenacDiclofenac pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be given intramuscular diclofenac 75mg 8hourly for first 24-hours after cesarean section

    Also known as: Diclofenac sodium, Voltarol

  • DrugDiclofenacStudies of DiclofenacDiclofenac pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be given diclofenac suppository every 8 hours for first 24-hours after cesarean section

06

What researchers measure

Primary outcomes

  1. Postoperative pain

    Pain will be assessed on visual analog scale by the blinded assessor

    Time frame: Pain will be assessed at 1, 6, 12 and 24-hours after cesarean section

Secondary outcomes

  1. Rescue Analgesia

    In cases of VAS \> 4, extra analgesia (rescue analgesia) will be given to control pain

    Time frame: From cesarean section to 24-hours postoperatively

07

Study locations

1 site
  • CMH Multan Institute of Medical Sciences
    Multan, Punjab Province 60000, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Jul 2025, 5 months.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 5 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Jan 30, 2026
StartActual
Feb 1, 2025
Primary completionActual
Jul 31, 2025
CompletionActual
Jul 31, 2025
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07379762
Lead sponsor
CMH Multan Institute of Medical Sciences
Responsible party
Rimsha Irshad (Principal Investigator, CMH Multan Institute of Medical Sciences) — Principal investigator
First posted
Jan 30, 2026
Start date
Feb 1, 2025
Primary completion
Jul 31, 2025
Completion
Jul 31, 2025
Last update
Jan 30, 2026

Study contacts

Nidda Y Assistant Professor, FCPS
study chair · CMH Multan Institute of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diclofenac

Start the discussion